Rakovina Therapeutics Stock Current Ratio
RKV Stock | CAD 0.17 0.02 10.53% |
Rakovina Therapeutics fundamentals help investors to digest information that contributes to Rakovina Therapeutics' financial success or failures. It also enables traders to predict the movement of Rakovina Stock. The fundamental analysis module provides a way to measure Rakovina Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rakovina Therapeutics stock.
Rakovina | Current Ratio |
Rakovina Therapeutics Company Current Ratio Analysis
Rakovina Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition |
In accordance with the recently published financial statements, Rakovina Therapeutics has a Current Ratio of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current ratio for all Canada stocks is 100.0% higher than that of the company.
Rakovina Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rakovina Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rakovina Therapeutics could also be used in its relative valuation, which is a method of valuing Rakovina Therapeutics by comparing valuation metrics of similar companies.Rakovina Therapeutics is currently under evaluation in current ratio category among its peers.
Rakovina Fundamentals
Return On Equity | -0.67 | ||||
Return On Asset | -0.27 | ||||
Current Valuation | 17.84 M | ||||
Shares Outstanding | 90.29 M | ||||
Shares Owned By Insiders | 31.94 % | ||||
Number Of Shares Shorted | 904 | ||||
Price To Book | 5.43 X | ||||
EBITDA | (2.16 M) | ||||
Net Income | (2.61 M) | ||||
Cash And Equivalents | 4.37 M | ||||
Cash Per Share | 0.06 X | ||||
Total Debt | 1.49 M | ||||
Book Value Per Share | 0.05 X | ||||
Cash Flow From Operations | (1.86 M) | ||||
Short Ratio | 0.01 X | ||||
Earnings Per Share | (0.04) X | ||||
Beta | 0.046 | ||||
Market Capitalization | 16.7 M | ||||
Total Asset | 5.15 M | ||||
Retained Earnings | (10.93 M) | ||||
Working Capital | 477.88 K | ||||
Net Asset | 5.15 M |
About Rakovina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rakovina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rakovina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rakovina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.